The launch of AlbuFree™ DX underscores Dyadic’s strategy to prioritize recombinant protein products that have clear commercial pathways and are supported by well-established end markets. Under the ...

Expanding existing COVID-19 vaccine research collaboration which began in July 2020. Medytox and Dyadic to co-develop C1 enabled COVID-19 vaccines and/or boosters which will immunize people against ...

Webcast Link:. https://viavid.webcasts.com/starthere.jsp?ei=1706029&tp_key=b177e95e36. An archive of the webcast will be available within 24 hours after completion of ...

Dyadic International (NASDAQ:DYAI) reported Q2 2025 earnings on August 13, 2025, delivering GAAP revenue of $967,000, representing a year-over-year increase over Q2 2024 and the company’s clearest ...

Improving patient outcomes, satisfaction and safety while using resources responsibly is foundational to the ever-changing world of kidney health care delivery. Leadership that succeeds clinically and ...

Dyadic International said today it will sell its industrial technology business to DuPont’s Industrial Biosciences business for $75 million cash, in a deal that will reposition the seller exclusively ...

Webcast Link: https://viavid.webcasts.com/starthere.jsp?ei=1705993&tp_key=2267a6328b. An archive of the webcast will be available within 24 hours after completion of ...

JUPITER, Fla., May 7, 2013 /PRNewswire/ -- Dyadic International, Inc. ("Dyadic") (OTC Pink: DYAI), a global biotechnology company focused on the discovery, development, manufacture and sale of enzyme ...

JUPITER, Fla., July 30, 2014 /PRNewswire/ -- Dyadic International, Inc. ("Dyadic") (OTCQX: DYAI), is a global biotechnology company whose patented and proprietary technologies are used to discover, ...

Dyadic International and Cygnus Technologies formed a strategic partnership for the quantification of host cell proteins (HCPs) from the filamentous fungus Thermothelomyces heterothallica C-1 cells.

The companies have entered into a sub-licensing agreement to develop products based on Dyadic’s C1 expression platform and Alphazymes’ enzyme technology. On May 6, 2019, Dyadic International, a ...

Aiming for the courtroom equivalent of a pin, former collegiate wrestler Mark Emalfarb alleged blue-chip law firms robbed his biotech company of $185 million in vanished market capitalization and $700 ...